Accuray (ARAY)

Executive Summary

Accuray is a global leader in precision radiotherapy, offering the CyberKnife and Radixact systems for stereotactic radiosurgery and image-guided radiotherapy. The company serves a growing oncology market, with its platforms differentiated by real-time motion tracking and adaptive therapy capabilities. Despite competitive pressures from industry giants like Varian and Elekta, Accuray has maintained a niche in complex cases and in emerging markets where its compact systems offer cost advantages. Financially, the company has faced revenue volatility but has recently shown improvement driven by increased system placements and recurring service revenue. Its installed base exceeding 800 systems provides a stable recurring revenue stream.

Upcoming Catalysts (preview)

• Q3 2026Q3 FY2026 Earnings Release90% success
• Q4 2026FDA 510(k) Clearance for New Radixact Software Module60% success
• H1 2027Strategic Partnership in Asia-Pacific40% success